Ileal MVL is predictive of therapeutic response to ustekinumab in CD patients from UNITI-2. (A) Ileal MVL is an effect modifier of clinical response to ustekinumab (N = 95). (C) Clinical remission to ustekinumab stratified by pretreatment ileal MVL (N = 95). (D) Endoscopic response to ustekinumab stratified by pretreatment ileal MVL (N = 71).